Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some of the most important updates in the treatment of FLT3-mutated acute myeloid leukemia (AML) presented at the ASH 2021 Annual Meeting. Dr Ravandi highlights studies evaluating combinations of FLT3 inhibitors such as gilteritinib, midostaurin and quizartinib with venetoclax and with chemotherapy, as well as triplet combination regimens with decitabine, venetoclax and quizartinib, and azacitidine, venetoclax and gilteritinib. He also comments on the development of menin inhibitors and their potential role in NPM1/FLT3-mutated AML. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

свернуть